CompletedPhase 3NCT01120249
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Christopher W. Ryan, MDOHSU Knight Cancer Institute
- Intervention
- everolimus(drug)
- Enrollment
- 1545 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2011 – 2025
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Gulf Coast MBCCOP, Mobile, Alabama, United States
- Providence Hospital, Mobile, Alabama, United States
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Arizona Cancer Center at UMC Orange Grove, Tucson, Arizona, United States
- Arizona Cancer Center at University Medical Center North, Tucson, Arizona, United States
- University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Veteran's Administration Medical Center, Little Rock, Arkansas, United States
- Kaiser Anaheim Medical Center, Anaheim, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Kaiser Permanente Medical Group - Baldwin Park, Baldwin Park, California, United States
- Kaiser Foundation Hospital, Bellflower, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01120249 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →